Björn Holzhauer
About
Björn Holzhauer is a scholar working on Cardiology and Cardiovascular Medicine, Statistics and Probability and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Björn Holzhauer has authored 33 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 9 papers in Statistics and Probability and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Björn Holzhauer's work include Blood Pressure and Hypertension Studies (9 papers), Statistical Methods in Clinical Trials (9 papers) and Asthma and respiratory diseases (6 papers). Björn Holzhauer is often cited by papers focused on Blood Pressure and Hypertension Studies (9 papers), Statistical Methods in Clinical Trials (9 papers) and Asthma and respiratory diseases (6 papers). Björn Holzhauer collaborates with scholars based in Switzerland, United States and United Kingdom. Björn Holzhauer's co-authors include Richard Kay, Stevo Julius, Tsushung A. Hua, Sverre E. Kjeldsen, Michael A. Weber, Alberto Zanchetti, Dion Zappe, Giuseppe Mancia, Gerald Bacher and Ruth Hartley and has published in prestigious journals such as Circulation, American Journal of Respiratory and Critical Care Medicine and European Heart Journal.
In The Last Decade
Björn Holzhauer
33 papers receiving 758 citations
Peers
Björn Holzhauer
Pamela F. Schwartz United States
Anja Schiel Norway
Jeremy Puthumana United States
Steven Bird United States
Stephen T. Vernon Australia
Pika Meško Brguljan Slovenia
Trefor Higgins Canada
Diogo Mendes Portugal
Jessica Bon United States
Jetty A. Overbeek Netherlands
Citations per year, relative to Björn Holzhauer Björn Holzhauer (= 1×)
peers
Pamela F. Schwartz
Countries citing papers authored by Björn Holzhauer
Since
Specialization
Citations
This map shows the geographic impact of Björn Holzhauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn Holzhauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn Holzhauer more than expected).
Fields of papers citing papers by Björn Holzhauer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Björn Holzhauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn Holzhauer. The network helps show where Björn Holzhauer may publish in the future.
Co-authorship network of co-authors of Björn Holzhauer
This figure shows the co-authorship network connecting the top 25 collaborators of Björn Holzhauer. A scholar is included among the top collaborators of Björn Holzhauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn Holzhauer. Björn Holzhauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Holzhauer, Björn, et al.. (2023). “Super‐covariates”: Using predicted control group outcome as a covariate in randomized clinical trials. Pharmaceutical Statistics. 22(6). 1062–1075.
2.
Holzhauer, Björn, Lisa V. Hampson, John Paul Gosling, et al.. (2022). Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study. Pharmaceutical Statistics. 21(5). 1005–1021.
3.
Price, David, Rupert Jones, Pascal Pfister, et al.. (2021). Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. PubMed. Volume 12. 25–35.
4.
Hampson, Lisa V., Björn Bornkamp, Björn Holzhauer, et al.. (2021). Improving the assessment of the probability of success in late stage drug development. Pharmaceutical Statistics. 21(2). 439–459.
5.
Holzhauer, Björn, Stevo Julius, Sverre E. Kjeldsen, et al.. (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure. 30(2). 82–89.
6.
Holzhauer, Björn, Stevo Julius, Sverre E. Kjeldsen, et al.. (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure. 30(2). 90–97.
7.
Ställberg, Björn, Karin Lisspers, Kjell Larsson, et al.. (2021). Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning – Based on the ARCTIC Study. International Journal of COPD. Volume 16. 677–688.
8.
Lisspers, Karin, Björn Ställberg, Kjell Larsson, et al.. (2021). Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients’ data using machine learning - Based on the ARCTIC study. Respiratory Medicine. 185. 106483–106483.
9.
Siah, Kien Wei, Nicholas Kelley, Björn Holzhauer, et al.. (2021). Predicting drug approvals: The Novartis data science and artificial intelligence challenge. Patterns. 2(8). 100312–100312.
10.
Bateman, Eric D., Florian Brockhaus, Björn Holzhauer, et al.. (2017). Fevipiprant, an oral prostaglandin DP2receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. European Respiratory Journal. 50(2). 1700670–1700670.
11.
Holzhauer, Björn, et al.. (2017). Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis. Statistics in Medicine. 37(6). 867–882.
12.
Aksnes, Tonje A., Sverre E. Kjeldsen, Morten Rostrup, et al.. (2016). Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Blood Pressure. 25(4). 235–240.
13.
Holzhauer, Björn. (2016). Meta-analysis of aggregate data on medical events. Statistics in Medicine. 36(5). 723–737.
14.
Gonem, Sherif, Rachid Berair, Amisha Singapuri, et al.. (2016). Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine. 4(9). 699–707.
15.
Berair, Rachid, Sherif Gonem, Amisha Singapuri, et al.. (2015). Effect Of Qaw039, An Oral Prostaglandin D2 Receptor (dp2/crth2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 191.
16.
Kjeldsen, Sverre E., Sripal Bangalore, Franz H. Messerli, et al.. (2015). Abstract 10123: Evidence Against the J-shaped Curve in Treated Hypertensive Patients With Increased Cardiovascular Risk: The VALUE Trial. Circulation. 132(suppl_3).
17.
Kjeldsen, Sverre E., Eivind Berge, Sripal Bangalore, et al.. (2015). No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Pressure. 25(2). 83–92.
18.
Howard, Campbell P., Adele Noè, Andrej Skerjanec, et al.. (2014). Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovascular Diabetology. 13(1). 94–94.
19.
Julius, Stevo, Paolo Palatini, Sverre E. Kjeldsen, et al.. (2011). Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension. The American Journal of Cardiology. 109(5). 685–692.
20.
Krum, Henry, John J.V. McMurray, Edward S. Horton, et al.. (2010). Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. Cardiovascular Therapeutics. 28(2). 124–132.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Pamela F. Schwartz Breakdown of academic impact, for papers by Anja Schiel Breakdown of academic impact, for papers by Jeremy Puthumana Breakdown of academic impact, for papers by Steven Bird Breakdown of academic impact, for papers by Stephen T. Vernon Breakdown of academic impact, for papers by Pika Meško Brguljan Breakdown of academic impact, for papers by Trefor Higgins Breakdown of academic impact, for papers by Diogo Mendes Breakdown of academic impact, for papers by Jessica Bon Breakdown of academic impact, for papers by Jetty A. Overbeek